

APR 30 2007

=== COVER PAGE ===

TO: \_\_\_\_\_

FROM: MALLINCKRODT PATENT

FAX: 1-314-654-3156

TEL: 1-314-654-8622

COMMENT:

**RECEIVED  
CENTRAL FAX CENTER****APR 30 2007****Facsimile Transmission**

<b>To:</b>	Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 ATTN: Claytor, Deirdre Renee	<b>Michelle DeCorte</b> IP Administrative Assistant Mallinckrodt Inc. 675 McDonnell Blvd. P.O. Box 5840 St. Louis, Missouri 63134 Telephone 314-654-3816 Facsimile 314-654-3156 E-Mail: patents@tycohealthcare.com
<b>Facsimile Number:</b>	Re: Response to Restriction 571-273-8300	
<b>Date:</b>	30-April-2007	
<b>Number of Pages (including cover):</b>	3	

**PLEASE SEE ATTACHED CORRESPONDENCE FOR USSN 10/554,133  
FILED OCTOBER 20, 2005.**

\*\*\*\*\*  
THIS FACSIMILE CONTAINS PRIVILEGED AND CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE  
INDIVIDUAL OR ENTITY NAMED ABOVE. IF THE READER OF THE FACSIMILE IS NOT THE INTENDED RECIPIENT OR  
THE EMPLOYEE OR AGENT RESPONSIBLE FOR DELIVERING IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY  
NOTIFIED THAT ANY DISSEMINATION OR COPYING OF THIS FACSIMILE IS STRICTLY PROHIBITED. IF YOU HAVE  
RECEIVED THIS FACSIMILE IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE AND RETURN THE  
ORIGINAL FACSIMILE TO US AT THE ABOVE ADDRESS VIA THE U.S. POSTAL SERVICE. THANK YOU.

RECEIVED  
CENTRAL FAX CENTER

APR 30 2007

1332 WO/US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Herman, Clifford J. :  
: Examiner: Claytor, Deirdre Renee  
: Serial No.: 10/554,133 : Group Art Unit: 1617  
: Filed: October 20, 2005 : Attorney Docket No.: 1332 WO/US  
: For: Methylphenidate Solution and :  
: Associated Methods of Administration :  
: And Production :

**RESPONSE TO RESTRICTION**

Mail Stop Non-Fee Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This letter is in response to the Office action mailed March 29, 2007 in which a restriction of a distinct invention was requested.

The Office action requires restriction to one of the following:

Group I – Claims 1-23, drawn to a methylphenidate solution comprising methylphenidate and at least one pharmaceutically acceptable organic acid.

Group II – Claims 24-34 and 50, drawn to a method of treating a patient for a disorder treatable by methylphenidate which comprises administering a therapeutically effective amount of methylphenidate in a liquid solution.